TABLE 5

Individuals at Higher Risk of Influenza Complications Recommended for Antiviral Treatment of Suspected/Confirmed Influenza

Children <2 y
Adults ≥65 y
Individuals with chronic pulmonary (including asthma), cardiovascular (except hypertension alone), renal, hepatic, hematologic (including sickle cell disease), or metabolic disorders (including diabetes mellitus) or neurologic and neurodevelopment conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy [seizure disorders], stroke, intellectual disability [mental retardation], moderate to severe developmental delay, muscular dystrophy, or spinal cord injury)
Individuals with immunosuppression, including that caused by medications or by HIV infection
Women who are pregnant or postpartum (within 2 wk after delivery)
Individuals aged <19 y who are receiving long-term aspirin therapy
American Indian/Alaska Native individuals
Individuals who are morbidly obese (ie, BMI ≥40)
Residents of nursing homes and other chronic care facilities
  • Source: Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM; Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1–24.